Company Overview and News

 
ARCC / Ares Capital Corp. DEFA14A

15h sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

 
ARCC / Ares Capital Corp. DEFA14A

15h sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION

 
BDCs move to boost leverage

2018-04-17 reuters
NEW YORK, April 17 (LPC) - Some Business Development Companies (BDCs) have already received board approval to increase the amount of debt that they can borrow after US legislation passed in March allowed them to double leverage on their funds.

10
Missed A Hot IPO? Subscriptions Soar Towards 5 Million At This Startup

2018-04-14 seekingalpha
We'll discuss an opportunity to dip your toes into the warming waters of a new entertainment technology company, growing like a weed.

 
Ares Capital: Better Times Lie Ahead

2018-04-11 seekingalpha
Performance in FY2017 has been weaker than expected on a per share basis, partly due to the dilution caused by the American Capital acquisitions.

 
Buy This Blue Chip BDC, Yield 9.6% At A Discount, Insiders Are Buying

2018-04-11 seekingalpha
ARCC is a battle-tested BDC company with solid history of outperformance and a conservative portfolio management strategy.

 
Sticks And Stones Break My Bones But Trade Threats Never Harm These Stocks

2018-04-08 seekingalpha
Escalating tariff threats are now like the proverbial snowball rolling down the hill, gathering mass along its path.

 
All-Out Trade War Looms - These Dividend Stocks Remain A Hedge

2018-04-06 seekingalpha
A tit-for-tat on tariffs threatens to spiral out of control as the president raised the stakes, threefold, after trading ended Thursday.

 
The (Chinese) Empire Strikes Back: This Dividend Stock Soars

2018-04-04 seekingalpha
On the domestic front, Amazon continues to draw the president's ire and the Nasdaq suffers collateral damage.

 
3 Largest Business Development Companies Take Steps To Increase Returns To Shareholders

2018-04-03 seekingalpha
Over the last few days, the largest BDCs have released SEC filings showing that their Boards are seeking to take advantage of the recently relaxed regulations for the sector.

 
Three Largest Business Development Companies Take Steps To Increase Returns To Shareholders

2018-04-03 seekingalpha
Over the last few days, the largest BDCs have released SEC filings showing that their Boards are seeking to take advantage of the recently relaxed regulations for the sector.

 
This Dividend Stock Gave Up Just 30% Of The S&P 500's Value Collapse

2018-04-03 seekingalpha
Iron Mountain stands like a rock against fear and dread and offers 25% higher income than its normal yield.

 
Prospect Capital's Dividend And NAV Sustainability Analysis - Part 2 (Including May-August 2018 Dividend Projection)

2018-04-02 seekingalpha
Part 2 of this article discusses three topics/trends impacting PSEC’s future dividend and NAV sustainability (forward-looking metrics).

 
ARCC / Ares Capital Corp. 8-K (Current Report)

2018-04-02 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 04010L103